Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AGRX
- CUSIP: N/A
- Web: www.agiletherapeutics.com
- Market Cap: $110.62 million
- Outstanding Shares: 28,806,000
- 50 Day Moving Avg: $3.57
- 200 Day Moving Avg: $3.44
- 52 Week Range: $1.82 - $8.15
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.40
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.24 per share
- Price / Book: 3.10
- EBIDTA: ($29,850,000.00)
- Return on Equity: -71.92%
- Return on Assets: -49.02%
- Debt-to-Equity Ratio: 0.26%
- Current Ratio: 3.82%
- Quick Ratio: 3.82%
- Average Volume: 206,414 shs.
- Beta: 1.81
- Short Ratio: 5.92
Frequently Asked Questions for Agile Therapeutics (NASDAQ:AGRX)
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its quarterly earnings results on Monday, August, 8th. The company reported ($0.29) EPS for the quarter, hitting analysts' consensus estimates of ($0.29). View Agile Therapeutics' Earnings History.
When will Agile Therapeutics make its next earnings announcement?
Where is Agile Therapeutics' stock going? Where will Agile Therapeutics' stock price be in 2017?
5 brokers have issued 1-year target prices for Agile Therapeutics' shares. Their predictions range from $8.00 to $15.00. On average, they expect Agile Therapeutics' share price to reach $11.40 in the next twelve months. View Analyst Ratings for Agile Therapeutics.
What are analysts saying about Agile Therapeutics stock?
Here are some recent quotes from research analysts about Agile Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Undervalued Asset: Following the January results of the Phase 3 SECURE trial, shares have struggled. Following two KOL calls discussed in our April note, however, we continue to believe that AGRX has delivered on what the FDA had previously asked of them following the original CRL and that TWIRLA is an approvable product." (5/8/2017)
- 2. According to Zacks Investment Research, "Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. " (3/13/2017)
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include Zymeworks (ZYME), DURECT Corporation (DRRX), Pieris Pharmaceuticals (PIRS), UROGEN PHARMA (URGN), Faron Pharmaceuticals Oy (FARN), Kindred Biosciences (KIN), ObsEva SA (OBSV), Cascadian Therapeutics (CASC), XBiotech (XBIT), Madrigal Pharmaceuticals (MDGL), Foamix Pharmaceuticals (FOMX), Athersys (ATHX), Oxford BioMedica plc (OXB), CymaBay Therapeutics (CBAY), OncoCyte Corp (OCX), vTv Therapeutics (VTVT), Redhill Biopharma (RDHL) and Kura Oncology (KURA).
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Alfred Altomari, Chairman of the Board, President, Chief Executive Officer
- Scott M. Coiante, Chief Financial Officer, Vice President
- Elizabeth Garner M.D., Senior Vice President, Chief Medical Officer
- Renee Selman, Chief Commercial Officer
- Abhijeet J. Lele, Lead Independent Director
- John W. Hubbard Ph.D., Director
- Ajit S. Shetty Ph.D., Director
- James Patrick Tursi M.D., Director
- Seth H. Z. Fischer, Independent Director
Who owns Agile Therapeutics stock?
Agile Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include ProQuest Associates IV LLC (17.57%), Aisling Capital LLC (0.00%), Royce & Associates LP (0.00%), Vanguard Group Inc. (0.00%), Geode Capital Management LLC (0.00%) and Bank of New York Mellon Corp (0.20%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Jay Moorin and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.
Who sold Agile Therapeutics stock? Who is selling Agile Therapeutics stock?
Who bought Agile Therapeutics stock? Who is buying Agile Therapeutics stock?
Agile Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari, Jay Moorin and Renee Selman. View Insider Buying and Selling for Agile Therapeutics.
How do I buy Agile Therapeutics stock?
Shares of Agile Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Agile Therapeutics stock can currently be purchased for approximately $3.84.
Earnings History for Agile Therapeutics (NASDAQ:AGRX)Earnings History by Quarter for Agile Therapeutics (NASDAQ AGRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2017|| || || || || || || || |
Earnings Estimates for Agile Therapeutics (NASDAQ:AGRX)
2017 EPS Consensus Estimate: ($1.18)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Agile Therapeutics (NASDAQ:AGRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Agile Therapeutics (NASDAQ:AGRX)
Insider Ownership Percentage: 3.50%Insider Trades by Quarter for Agile Therapeutics (NASDAQ:AGRX)
Institutional Ownership Percentage: 79.78%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/11/2017||Alfred Altomari||Chairman||Buy||10,000||$3.51||$35,100.00|| |
|5/11/2017||Renee Selman||Insider||Buy||53,333||$3.68||$196,265.44|| |
|1/27/2016||Jay Moorin||Major Shareholder||Buy||393,700||$6.35||$2,499,995.00|| |
|6/2/2015||Alfred Altomari||CEO||Buy||2,500||$8.73||$21,825.00|| |
|1/23/2015||Jay Moorin||Major Shareholder||Buy||811,966||$5.85||$4,750,001.10|| |
|5/29/2014||Care Capital Iii Llc||Major Shareholder||Buy||500,000||$6.00||$3,000,000.00|| |
|5/23/2014||Andrew N Schiff||Director||Buy||1,333,333||$6.00||$7,999,998.00|| |
|5/22/2014||Ab Investor||Major Shareholder||Buy||1,000,000||$6.00||$6,000,000.00|| |
Headline Trends for Agile Therapeutics (NASDAQ:AGRX)
Latest Headlines for Agile Therapeutics (NASDAQ:AGRX)
|Agile Therapeutics, Inc. (AGRX) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - June 23 at 10:06 AM
|BUZZ-U.S. STOCKS ON THE MOVE-Booz Allen, Yamana Gold, Hornbeck Offshore|
www.nasdaq.com - June 16 at 3:55 PM
|Noble Financial Reaffirms "Buy" Rating for Agile Therapeutics, Inc. (AGRX)|
www.americanbankingnews.com - June 14 at 7:32 AM
|Agile Therapeutics Inc (AGRX) Expected to Announce Earnings of -$0.28 Per Share|
www.americanbankingnews.com - May 31 at 6:28 PM
|Agile Therapeutics Inc (AGRX) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - May 29 at 9:32 AM
|Agile Therapeutics Inc (AGRX) Forecasted to Post Q2 2017 Earnings of ($0.25) Per Share|
www.americanbankingnews.com - May 17 at 8:10 AM
|AGRX: Initiating Coverage of Agile Therapeutics; NDA for Weekly Contraceptive Patch Set to Be Filed…|
finance.yahoo.com - May 15 at 3:24 PM
|Equities Analysts Set Expectations for Agile Therapeutics Inc's FY2017 Earnings (AGRX)|
www.americanbankingnews.com - May 12 at 1:20 PM
|Insider Buying: Agile Therapeutics Inc (AGRX) Insider Acquires 53,333 Shares of Stock|
www.americanbankingnews.com - May 12 at 10:17 AM
|Agile Therapeutics Inc (AGRX) Chairman Acquires $35,100.00 in Stock|
www.americanbankingnews.com - May 12 at 10:16 AM
|FY2017 EPS Estimates for Agile Therapeutics Inc (AGRX) Raised by Analyst|
www.americanbankingnews.com - May 11 at 11:42 AM
|Agile Therapeutics Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)|
globenewswire.com - May 9 at 3:25 PM
|FDA Snubs TXMD, AGRX To Try Luck Again, CYTK Abuzz, ROKA Surges After-Hours|
www.rttnews.com - May 9 at 9:25 AM
|Agile Therapeutics Inc (AGRX) Given "Buy" Rating at Cantor Fitzgerald|
www.americanbankingnews.com - May 8 at 10:16 PM
|Agile Therapeutics Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 8 at 8:22 PM
|Agile Therapeutics reports 1Q loss|
marketbeat.com - May 8 at 5:36 PM
|Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017 - GlobeNewswire (press release)|
globenewswire.com - May 8 at 3:21 PM
|TXMD All Set For D-day, IMMU Soars On Strategic Plan, CTSO On Watch|
www.rttnews.com - May 7 at 3:26 PM
|Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017|
finance.yahoo.com - May 6 at 3:52 PM
|Agile Therapeutics Inc (AGRX) Set to Announce Earnings on Monday|
www.americanbankingnews.com - May 5 at 8:08 PM
|Agile Therapeutics Inc (AGRX) Expected to Announce Earnings of -$0.31 Per Share|
www.americanbankingnews.com - May 5 at 6:10 PM
|Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the ... - GlobeNewswire (press release)|
globenewswire.com - May 3 at 8:27 PM
|Agile Therapeutics (AGRX) Getting Somewhat Favorable Press Coverage, Analysis Finds|
www.americanbankingnews.com - May 2 at 9:24 AM
|Agile Therapeutics (AGRX) Receiving Positive Media Coverage, Analysis Finds|
www.americanbankingnews.com - April 28 at 9:01 AM
|Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women's Health - Yahoo Finance|
finance.yahoo.com - April 27 at 3:45 PM
|Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health|
finance.yahoo.com - April 27 at 3:45 PM
|Agile Therapeutics (AGRX) Earning Somewhat Positive Press Coverage, Report Shows|
www.americanbankingnews.com - April 25 at 2:31 PM
|Agile Therapeutics (AGRX) Receiving Positive Media Coverage, Study Shows|
www.americanbankingnews.com - April 21 at 9:01 AM
|Agile Therapeutics (AGRX) Earning Somewhat Positive Media Coverage, Report Finds|
www.americanbankingnews.com - April 18 at 10:48 AM
|Agile Therapeutics (AGRX) Getting Somewhat Positive Media Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 15 at 8:53 AM
|Agile Therapeutics (AGRX) Says it Has Necessary Info to Complete NDA Resubmission Following FDA Meeting - StreetInsider.com|
www.streetinsider.com - April 11 at 8:19 AM
|Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA|
finance.yahoo.com - April 11 at 8:19 AM
|Agile Therapeutics Inc (AGRX) Sees Large Increase in Short Interest|
www.americanbankingnews.com - April 8 at 7:26 AM
|Generic Drugs Stocks on Investors' Radar -- Diplomat Pharma, Momenta Pharma, Agile Therapeutics, and Sophiris Bio - PR Newswire (press release)|
www.prnewswire.com - April 7 at 7:21 AM
|Agile Therapeutics Inc (AGRX) Stock Rating Reaffirmed by Cantor Fitzgerald|
www.americanbankingnews.com - April 4 at 9:48 PM
|Agile Therapeutics Inc. (AGRX) Has Risen To Nearly A 3-Month High|
www.rttnews.com - March 29 at 3:32 PM
|Cantor Fitzgerald Weighs in on Agile Therapeutics Inc's FY2017 Earnings (AGRX)|
www.americanbankingnews.com - March 23 at 9:32 AM
|AGILE THERAPEUTICS INC Financials|
finance.yahoo.com - March 21 at 3:48 PM
|Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference|
www.nasdaq.com - March 16 at 4:56 PM
|AGILE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - March 16 at 4:56 PM
|AGILE THERAPEUTICS INC Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 15 at 8:37 PM
|Agile Therapeutics Inc (AGRX) Earns “Buy” Rating from Noble Financial|
www.americanbankingnews.com - March 13 at 10:49 PM
|Agile Therapeutics Inc Expected to Earn Q1 2017 Earnings of ($0.30) Per Share (AGRX)|
www.americanbankingnews.com - March 13 at 11:38 AM
|Agile Therapeutics Inc (AGRX) Rating Increased to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 13 at 10:06 AM
|Agile Therapeutics Inc (AGRX) Given a $10.00 Price Target at FBR & Co|
www.americanbankingnews.com - March 12 at 9:27 PM
|Agile Therapeutics Reports Fourth Quarter and Full Year 2016 ... - GlobeNewswire (press release)|
globenewswire.com - March 9 at 3:28 PM
|Agile Therapeutics Inc (AGRX) Releases Earnings Results, Misses Estimates By $0.01 EPS|
www.americanbankingnews.com - March 9 at 12:22 PM
|Agile Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results|
us.rd.yahoo.com - March 9 at 1:35 AM
|4:19 pm Agile Therapeutics reports Q4 results, provides corporate update|
us.rd.yahoo.com - March 9 at 1:35 AM
|AGILE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex|
us.rd.yahoo.com - March 9 at 1:35 AM
Agile Therapeutics (AGRX) Chart for Sunday, June, 25, 2017